Crescita Therapeutics (CTX) Q4 2025 earnings summary

Executive summary

• Fiscal 2025 revenue increased to $21.1M from $19.6M year-over-year, driven by acquisitions and higher e-commerce sales.

• Net loss narrowed significantly to $92K from $2.75M year-over-year, reflecting improved operational performance and one-time items.

• Adjusted EBITDA turned positive at $617K versus a loss of $1.54M in the prior year.

• Q4-2025 revenue declined to $6.0M from $6.9M, but gross profit rose to $3.2M due to higher-margin sales.

• Announced all-cash acquisition by ClinActiv Holdings at a 74% premium, pending shareholder and court approval.

Financial highlights

• Q4-2025 gross margin improved to 54.4% from 40.7% year-over-year.

• Operating expenses for the year decreased slightly to $12.1M from $12.2M.

• Cash and cash equivalents at year-end were $8.6M, down $696K from the prior year.

• Cash provided by operating activities was $1.1M for the year.

Outlook and guidance

• Management remains focused on operational execution and customer service while seeking approvals for the ClinActiv acquisition.

• The transaction is expected to close in Q2 2026, with shares to be delisted upon completion.